Data Protection in China: 17 Years after China's WTO Accession

Wenting Cheng

Data Protection in China: 17 Years after China's WTO Accession

Wenting Cheng

Research output: Contribution to journal › Article › peer-review

Abstract

China introduced dual data protection (both undisclosed information and six-year data exclusivity) for pharmaceutical products from its accession to the WTO. From 2017, a new series of policies proposed up to 12 years of data exclusivity for biologics. The drug negotiation mechanism in China should be considered in evaluating the impacts of these policies on enhanced data protection

Original language	English
Pages (from-to)	292-297
Journal	European Intellectual Property Review (E.I.P.R)
Volume	41
Issue number	5
Publication status	Published - 2018

Cite this

@article{e0ada4e0db0b46a39660695096aa1c49,

title = "Data Protection in China: 17 Years after China's WTO Accession",

abstract = "China introduced dual data protection (both undisclosed information and six-year data exclusivity) for pharmaceutical products from its accession to the WTO. From 2017, a new series of policies proposed up to 12 years of data exclusivity for biologics. The drug negotiation mechanism in China should be considered in evaluating the impacts of these policies on enhanced data protection",

author = "Wenting Cheng",

year = "2018",

language = "English",

volume = "41",

pages = "292--297",

journal = "European Intellectual Property Review (E.I.P.R)",

publisher = "Sweet & Maxwell Ltd",

number = "5",

}

TY - JOUR

T1 - Data Protection in China: 17 Years after China's WTO Accession

AU - Cheng, Wenting

PY - 2018

Y1 - 2018

N2 - China introduced dual data protection (both undisclosed information and six-year data exclusivity) for pharmaceutical products from its accession to the WTO. From 2017, a new series of policies proposed up to 12 years of data exclusivity for biologics. The drug negotiation mechanism in China should be considered in evaluating the impacts of these policies on enhanced data protection

AB - China introduced dual data protection (both undisclosed information and six-year data exclusivity) for pharmaceutical products from its accession to the WTO. From 2017, a new series of policies proposed up to 12 years of data exclusivity for biologics. The drug negotiation mechanism in China should be considered in evaluating the impacts of these policies on enhanced data protection

M3 - Article

VL - 41

SP - 292

EP - 297

JO - European Intellectual Property Review (E.I.P.R)

JF - European Intellectual Property Review (E.I.P.R)

IS - 5

ER -

Data Protection in China: 17 Years after China's WTO Accession

Abstract

Fingerprint

Cite this